Prostate cancer: Predicting risk of metastasis after prostatectomy
Sign Up to like & getrecommendations! Published in 2018 at "Nature Reviews Urology"
DOI: 10.1038/nrurol.2017.228
Abstract: Safety and efficacy of the anti-PDL1 antibody atezolizumab versus chemotherapy were assessed in the phase III trial IMvigor211 in 931 patients with metastatic urothelial carcinoma who had progressed after platinum-based chemotherapy. In patients with PDL1… read more here.
Keywords: chemotherapy; predicting risk; risk metastasis; prostate cancer ... See more keywords